Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Hartmut Döhner,1 Elihu H. Estey,2 Sergio Armandori,3 Frederick R. Appelbaum,4 Thomas Büchner,5 Alan K. Burnett,6 Hervé Dombret,7 Pierre Fenaux,8 David Grimwade,9 Richard A. Larson,10 Francesco Lo-Coco,11 Tomoki Naoe,12 Dietger Niederwieser,13 Gert J. Ossenkoppele,14 Miguel A. Sanz,15 Jorge Sierra,16 Martin S. Tallman,17 Bob Löwenberg,18 and Clara D. Bloomfield19

1Department of Internal Medicine III, University of Ulm, Ulm, Germany; 2Seattle Cancer Center Alliance, WA; 3Department of Hematology, Tor Vergata University Hospital, Rome, Italy; 4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 5Department of Hematology/Oncology, University of Münster, Münster, Germany; 6Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom; 7Institut Universitaire d'Hématologie Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; 8Service d'Hématologie Clinique, Hôpital Avicenne, Bobigny, France; 9Department of Medical and Molecular Genetics, Guy's King's and St. Thomas' School of Medicine, London, United Kingdom; 10Department of Medicine and Cancer Research Center, University of Chicago, IL; 11Department of Biopathology, University Tor Vergata and Santa Lucia Foundation at Centro Europeo per la Ricerca sul Cervello, Rome, Italy; 12Department of Hematology, Nagoya University Hospital, Showa-ku, Japan; 13Department of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany; 14Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands; 15Hematology and Bone Marrow Transplant Unit, University Hospital La Fe, Valencia, Spain; 16Clinical Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 17Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL; 18Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; and 19The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus

In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion–based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed. (Blood. 2010;115:453-474)

1. Introduction

In 1990 and 2003, expert working groups published recommendations for diagnosis, standardization of response criteria and treatment outcomes, and reporting standards for clinical trials in acute myeloid leukemia (AML).2,3 These have been widely adopted in general practice, within clinical trials, and by regulatory agencies. During recent years, considerable progress has been made in deciphering the molecular genetic and epigenetic basis of AML and in defining new diagnostic and prognostic markers. A growing number of recurring genetic changes have been recognized in the new World Health Organization (WHO) classification of AML.3 Furthermore, novel therapies are now being developed that target some of the genetic lesions. All these developments prompted an international expert panel to provide updated recommendations for the diagnosis and management of adult patients with AML, excluding acute promyelocytic leukemia (APL) for which recommendations were published separately.4 These recommendations provide standard requirements for general practice and for clinical trials. However, to accelerate progress in research the panel strongly recommends entry of AML patients on clinical trials, and storage of biosamples to enable correlative laboratory studies.

The following statements and recommendations are based on studies that predominantly were performed in the United States and Europe. Specific dosages and interventions may vary among different countries and populations.

2. Methods

2.1 Composition of the panel

The panel included 19 members with recognized clinical and research expertise in AML, of whom 13 came from European Union countries, 5 from the United States, and 1 from Japan. The panel met 4 times.

2.2 Scope of the review

Computerized literature searches of the PubMed, Cochrane, and Medline databases in the English language were conducted using key words relevant to the various sections of this article. Relevant abstracts presented at the 2006, 2007, and 2008 meetings of the American Society of Hematology, the European Hematology Association, and the American Society of Clinical Oncology were also reviewed. The categories of evidence and consensus were those used by the National Comprehensive Cancer Network (NCCN; www.nccn.org/professionals/physician_gls/PDF/aml.pdf). The vast majority of recommendations were category 2A recommendations, that is, they...
are based on low-level evidence and there is uniform panel consensus. The benefits are closely balanced with the risks and burdens, and the best action may differ depending upon circumstances.

3. WHO classification

The recent WHO classification reflects the fact that an increasing number of acute leukemias can be categorized based upon their underlying cytogenetic or molecular genetic abnormalities, and that these genetic changes form clinico-pathologic-genetic entities (Table 1). The subgroup “AML with recurrent genetic abnormalities” comprises several primary AML entities. “AML with t(8;21)(q22;q22); RUNX1-RUNX1T1” and “AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11” are considered as AML regardless of bone marrow blast counts. In “AML with t(15;17)(q22;q12); PML-RARA,” RARA translocations with other partner genes are recognized separately. The former category “AML with 11q23 (MLL) abnormalities” was redefined in that “AML with t(9;11)(p22;q23); MLLT3-MLL” is now a unique entity; balanced translocations other than that involving MLLT3 should be specified in the diagnosis. Three new cytogenetically defined entities were incorporated: “AML with t(6;9)(p23;q34); DEK-NUP214”; “AML with inv(3)(q21q26) or t(3;3)(q21;q26.2); RNPI-EVI7”; and “AML (megakaryoblastic) with t(1;22)(p13;q113); RBM15-MKLI,” a rare leukemia most commonly occurring in infants. Two new provisional entities defined by the presence of gene mutations were added, “AML with mutated NPM1 [nucleophosmin (nucleolar phosphoprotein B23, numatrin)],” and “AML with mutated CEBPA [CCAAT/enhancer binding protein (C/EBP), alpha].” There is growing evidence that these 2 gene mutations represent primary genetic lesions (so-called class II mutations) that impair hematopoietic differentiation. Mutations in the fms-related tyrosine kinase 3 (FLT3) gene are found in many AML subtypes and are considered class I mutations conferring a proliferation and/or survival advantage. AML with FLT3 mutations are not considered a distinct entity, although determining the presence of such mutations is recommended by WHO because they have prognostic significance.

The former subgroup termed “AML with multilineage dysplasia” is now designated “AML with myelodysplasia-related changes.” Dysplasia in 50% or more of cells, in 2 or more hematopoietic cell lineages, was the diagnostic criterion for the former subset. However, the clinical significance of this morphologic feature has been questioned. AMLs are now categorized as “AML with myelodysplasia-related changes” if (1) they have a previous history of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and evolve to AML with a marrow or blood blast count of 20% or more; (2) they have a myelodysplasia-related cytogenetic abnormality (listed in a footnote to Table 1); or (3) if 50% or more of cells in 2 or more myeloid lineages are dysplastic.

“Therapy-related myeloid neoplasms” has remained a distinct entity; however, since most patients have received treatment using both alkylating agents and drugs that target topoisomerase II for prior malignancy, a division according to the type of previous therapy is often not feasible. Therefore, therapy-related myeloid neoplasms are no longer subcategorized. Myeloid proliferations related to Down syndrome are now listed as distinct entities.

Table 1. Acute myeloid leukemia and related precursor neoplasms, and acute leukemias of ambiguous lineage (WHO 2008)

<table>
<thead>
<tr>
<th>Categories</th>
<th>Acute myeloid leukemia with recurrent genetic abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AML with t(8;21)(q22;q22); RUNX1-RUNX1T1</td>
</tr>
<tr>
<td></td>
<td>AML with inv(16)(p13.1q22) or t(16;16)(p13.1q22); CBFB-MYH11</td>
</tr>
<tr>
<td></td>
<td>AML with t(15;17)(q22;q12); PML-RARA*</td>
</tr>
<tr>
<td></td>
<td>AML with t(9;11)(p22;q33); MLLT3-MLL†</td>
</tr>
<tr>
<td></td>
<td>AML with (6;9)(p23;q34); DEK-NUP214</td>
</tr>
<tr>
<td></td>
<td>AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RNPI-EVI7</td>
</tr>
<tr>
<td></td>
<td>AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKLI</td>
</tr>
<tr>
<td></td>
<td>Provisional entity; AML with mutated NPM1</td>
</tr>
<tr>
<td></td>
<td>Provisional entity; AML with mutated CEBPA</td>
</tr>
</tbody>
</table>

Acute myeloid leukemia with myelodysplasia-related changes¶

Therapy-related myeloid neoplasms§

Acute myeloid leukemia, not otherwise specified (NOS)

Acute myeloid leukemia with minimal differentiation

Acute myeloid leukemia without maturation

Acute myeloid leukemia with maturation

Acute myelomonocytic leukemia

Acute monoblastic/monocytic leukemia

Acute erythroid leukemia

Pure erythroid leukemia

Erythroleukemia, erythroid/myeloid

Acute megakaryoblastic leukemia

Acute basophilic leukemia

Acute panmyelosis with myelofibrosis (syn.: acute myelofibrosis; acute myelosclerosis)

Myeloid sarcoma (syn.: extramedullary myeloid tumor; granulocytic sarcoma; chloroma)

Myeloid proliferations related to Down syndrome

Transient acute myeloplasia (syn.: transient myeloproliferative disorder)

Myeloid leukemia associated with Down syndrome

Blastic plasmacytoid dendritic cell neoplasm

Acute leukemias of ambiguous lineage

Acute undifferentiated leukemia

Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL f

Mixed phenotype acute leukemia with t(1;19)(q23;p13); MLL rearranged

Mixed phenotype acute leukemia, B/myeloid, NOS

Mixed phenotype acute leukemia, T/myeloid, NOS

Provisional entity: Natural killer (NK)-cell lymphoplastic leukemia/lymphoma

Adopted from reference 3; for a diagnosis of AML, a marrow blast count of ≥ 20% is required, except for AML with the recurrent genetic abnormalities t(1;15), t(8;21), inv(16) or t(16;16) and some cases of erythroleukemia.

*Other recurring translocations involving RARA should be reported accordingly: for example, AML with t(11;17)(q23;q12); ZBTB16-RARA; AML with t(11;17)(q13; q26.2); NUMA1-RARA; AML with t(6;17)(q55;q12); NPM1-RARA; or AML with STAT5B- RARA (the latter having a normal chromosome 17 on conventional cytogenetic analysis).

†Other translocations involving MLL should be reported accordingly: for example, AML with t(6;11)(q27;q23); MLLT4-MLL; AML with t(11;19)(q23;p13.3); MLL-MLLT1; AML with t(11;19)(q23;p13.1); MLL-ELL; AML with t(10;11)(p12;q23); MLLT10-MLL.

More than 20% blood or marrow blasts and any of the following: previous history of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN); myelodysplasia-related cytogenetic abnormality (see below); multilineage dysplasia; and absence of both prior cytotoxic therapy for unrelated disease and aforementioned recurring genetic abnormalities; cytogenetic abnormalities sufficient to diagnose AML with myelodysplasia-related changes are:

- Complex karyotype (defined as 3 or more chromosomal abnormalities).
- Unbalanced changes: −7 or del(7q); −5 or del(5q); (17q) or t(17p); −13 or del(13q); del(11q); del(12p) or t(12p); del(5q); idic(X)(q13).
- Balanced changes: t(11;16)(q23;p13.3); t(3;3)(q28.2;q22.1); t(13;13)(p36.3; q21.1); t(12;11)(p21;q33); t(5;5)(q33;q11.2); t(5:5)(q33;p13); t(5;10)(q33;q21); t(5;5)(q25;p34).
- §Cytotoxic agents implicated in therapy-related hematologic neoplasms: alkylating agents; ionizing radiation therapy; topoisomerase II inhibitors; others.

¶BCR-ABL f-positive leukemia may present as mixed phenotype acute leukemia, but should be treated as BCR-ABL f-positive acute lymphoblastic leukemia.
4. Diagnostic procedures

4.1 Morphology

A bone marrow aspirate is part of the routine diagnostic work-up of a patient with suspected AML. The panel considers a marrow trephine biopsy optional, but it should be performed in patients with a dry tap (puncito sicca).

Blood and marrow smears are morphologically examined using a May-Grünwald-Giemsia or a Wright-Giemsa stain. It is recommended that at least 200 leukocytes on blood smears and 500 nucleated cells on marrow smears be counted, with the latter containing spicules. For a diagnosis of AML, a marrow or blood blast count of 20% or more is required, except for AML with t(15;17), t(8;21), inv(16) or t(16;16), and some cases of erythroleukemia. Myeloblasts, monoblasts, and megakaryoblasts are included in the blast count. In AML with monocytic or myelomonocytic differentiation, monoblasts and promonocytes, but not abnormal monocytes, are counted as blast equivalents. Erythroblasts are not counted as blasts except in the rare instance of pure erythroid leukemia.

To identify lineage involvement some countries still rely more on cytochemistry, rather than on immunophenotyping (usually by flow cytometry), using myeloperoxidase (MPO) or Sudan black B (SBB) and nonspecific esterase (NSE) stains. Detection of MPO (if present in ≥3% of blasts) indicates myeloid differentiation, but its absence does not exclude a myeloid lineage because early myeloblasts and monoblasts may lack MPO. SBB staining parallels MPO but is less specific. NSE stains show diffuse cytoplasmic activity in monoblasts (usually >80% positive) and monocytes (usually >20% positive). In acute erythroid leukemia, a periodic acid-Schiff (PAS) stain may show large globules of PAS positivity. Iron stains may allow for the detection of iron stores, normal sideroblasts, and ring sideroblasts.

4.2 Immunophenotyping

Immunophenotyping using multiparameter (commonly at least 3- to 4-color) flow cytometry is used to determine lineage involvement of a newly diagnosed acute leukemia (Table 2).3,9,10 There is no general consensus on the cutoff point for considering an acute leukemia to be positive for a marker. For most markers, a commonly used criterion is 20% or more of leukemic cells expressing the marker,10 whereas for selected markers (eg, cytoplasmic CD3, MPO, TdT, CD34, CD117) a lower cutoff has been applied (10%). Quantification of expression patterns of several surface and cytoplasmic antigens is necessary for lineage assignment, to diagnose mixed phenotype acute leukemia (MPAL), and to detect aberrant immunophenotypes allowing for measurement of minimal residual disease (MRD). Flow cytometry determination of blast count should not be used as a substitute for morphologic evaluation.5

Immunophenotyping is required to establish the diagnosis of AML with minimal differentiation, acute megakaryoblastic leukemia, and acute leukemias of ambiguous lineage.5 AML with minimal differentiation is an AML without morphologic and cytochemical evidence of myeloid differentiation.11 Most cases express early hematopoiesis-associated antigens (eg, CD34, CD38, and HLA-DR) and lack most markers of myeloid and monocytic maturation; while MPO is negative by cytochemistry, detection of intracytoplasmic MPO antigens may be positive by flow cytometry in at least a fraction of blasts. Acute megakaryoblastic leukemia is a leukemia with 20% or more blasts of which 50% or more are of megakaryocytic lineage; megakaryoblasts typically express one or more of the platelet glycoproteins CD41 and/or CD61, and less commonly CD42. Acute leukemias of ambiguous lineage are rare leukemias and comprise those cases that show no evidence of lineage differentiation (ie, acute undifferentiated leukemia [AUL]) or those with blasts that express markers of more than one lineage (ie, MPAL). AULs often express HLA-DR, CD34, and/or CD38, but by definition lack lineage-associated markers. MPAL can either contain distinct blast populations of different lineages, or one blast population with markers of different lineages on the same cell, or a combination of both. MPAL as defined by WHO encompasses several subsets, with or without an underlying genetic abnormality (Table 1).

BCR-ABL1—positive acute leukemia immunophenotypically may present as MPAL (Table 1). Such leukemias should not be treated as AML, but rather as ALL with incorporation of an ABL1 tyrosine kinase inhibitor with chemotherapy. Also, in BCR-ABL1—positive leukemias, the differential diagnosis of chronic myelogenous leukemia (CML) blast crisis should be considered.

Some AMLs with recurrent genetic abnormalities are associated with characteristic immunophenotypic features. For example, AMLs with t(8;21) frequently express the lymphoid markers CD19 or, to a
lesser extent, CD7; they may also express CD56;12,13; AMLs with inv(16) frequently express the T lineage–associated marker CD2;16; and AMLs with NPM1 mutation typically have high CD33 but absent or low CD34 expression.15

4.3 Cytogenetics

Conventional cytogenetics analysis is a mandatory component in the diagnostic evaluation of a patient with suspected acute leukemia. Chromosome abnormalities are detected in approximately 55% of adult AML.6,17 Seven recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category “AML with recurrent genetic abnormalities.” Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of “AML with myelodysplasia-related features” when 20% or more blood or marrow blasts are present (Table 1).

A minimum of 20 metaphase cells analyzed from bone marrow is considered mandatory to establish the diagnosis of a normal karyotype, and recommended to define an abnormal karyotype. Abnormal karyotypes may be diagnosed from blood specimens.

4.4 Molecular cytogenetics

Methanol/acetic acid–fixed cell pellets should be stored so if cytogenetic analysis fails, fluorescence in situ hybridization (FISH) is an option to detect gene rearrangements, such as RUNX1-RUNX1T1, CBFB-MYH11, MLL and EVI1 gene fusions, or loss of chromosome 5q and 7q material.18,19 FISH is frequently necessary to identify MLL fusion partners in 11q23 translocations.

4.5 Molecular genetics

A marrow (and blood) specimen should routinely be taken for molecular diagnostics. Ideally, DNA and RNA should be extracted and viable cells stored; if cell numbers are limited, RNA extraction should be a priority, because RNA is suitable for molecular screening for fusion genes and leukemia-associated mutations.

Molecular diagnosis by reverse transcriptase–polymerase chain reaction (RT-PCR) for the recurring gene fusions, such as RUNX1-RUNX1T1, CBFB-MYH11, MLLT3-MLL, DEK-NUP214, can be useful in certain circumstances. RT-PCR, for which standardized protocols were published by the BIOMED-1 group,20 is an option to detect these rearrangements, if chromosome morphology is of poor quality, or if there is typical narrow morphology but the suspected cytogenetic abnormality is not present.21,22

Somatically acquired mutations have been identified in several genes, for example, the NPM1 gene,15 the FLT3 gene,23,24 the CEBPA gene,25 the myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) (MLL) gene,26 the neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) gene,27 the Wilms tumor 1 (WT1) gene,28 the v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) gene,29 the runt-related transcription factor 1 (RUNX1) gene,30 the tet oncogene family member 2 (TET2) gene,31,32 and the isocitrate dehydrogenase 1 (NADP+), soluble (IDH1) gene.33 The frequencies of these gene mutations vary among cytogenetic groups.34

AML with mutations in NPM1 or CEBPA have been incorporated in the WHO classification as provisional entities.7 Screening for these 2 markers as well as for FLT3 mutations should be done in clinical trials. While testing for NPM1, CEBPA, and FLT3 is currently not considered mandatory outside clinical trials, the panel recommends that these 3 mutations be analyzed at least in patients with cytogenetically normal AML. (CN-AML) who will receive treatment other than low-dose chemotherapy or best supportive care.

4.6 Genome-wide studies

Recent progress in genomics technology has resulted in the identification of novel genetic abnormalities and holds the promise of making the systematic characterization of cancer genomes feasible.35,36 For example, gene- and microRNA-expression profiling have proven valuable for the discovery of novel leukemia subgroups and of prognostic signatures.37-39 The introduction of genome-wide single nucleotide polymorphism (SNP)–based mapping arrays, providing both copy number and allele-specific information, led to the identification of a novel mechanism involved in the pathogenesis of AML, that is, uniparental disomy (UPD).40 Acquired UPD is due to a mitotic recombination event and may render a cell homozygous for a preexisting mutation located in the affected genomic region. The power of SNP genotyping as a tool for gene discovery is shown by several recent studies.31,32,41,42 While analyses of genomic copy number will continue to be informative with regard to selection of candidate leukemia genes, it is also hoped that high-throughput DNA sequence analysis will become possible at an affordable cost, which may ultimately result in the development of comprehensive, disease- and allele-specific oncogene mutation profiling strategies.35,43 Finally, functional genetic approaches, such as large-scale RNA interference screens, have great potential for the identification of novel cancer genes. An example is a recent study in which graded down-regulation of multiple candidate genes by RNA interference was used to identify RPS14 as a causal gene for the MDS syndrome.44

4.7 Biobanking

Within clinical trials, we strongly recommend storing patients’ pretreatment leukemic marrow and blood within a biobank. A prerequisite for biobanking is the patient’s informed consent that ideally should allow a broad spectrum of correlative laboratory studies that also include analysis of germline DNA. Pretreatment samples should include nucleic acid (DNA and RNA, stored at −80°C) and viable cells (stored at −196°C). For further optional storage, we advise saving germline DNA (eg, from a buccal swab, skin biopsy, or sputum), a plasma sample, a methanol/acetic acid–fixed cell pellet (from cytogenetic analysis), and frozen cell pellets from various time points during and after treatment (ie, at the time of complete remission [CR], at relapse; and for MRD monitoring at defined time points during treatment and follow-up), stored under appropriate conditions.

4.8 Other diagnostic tests

Additional diagnostic tests and procedures in the initial work-up of a patient with AML are given in Table 3.

5. Prognostic factors

Prognostic factors may be subdivided into those related to patient characteristics and general health condition and those related to characteristics particular to the AML clone. The former subset usually predicts treatment-related mortality (TRM) and becomes more important as patient age increases while the latter predicts resistance to, at least, conventional therapy.

5.1 Patient-related factors

Increasing age is an adverse prognostic factor.45,46 Even after accounting for risk factors, such as cytogenetics, molecular genetics, type of AML (ie, de novo AML; AML with previous history of
5.2 AML-related factors

AML-related prognostic factors includes white blood count (WBC), existence of prior MDS, previous cytotoxic therapy for another disorder (see section 9), and cytogenetic and molecular genetic changes in the leukemic cells at diagnosis. Various other factors, such as splenomegaly and elevated serum lactate dehydrogenase (LDH) levels, have been reported to confer some prognostic effect but with variable consistency among studies. The significance of a prognostic factor is always dependent on the therapy given to a patient.

5.2.1 Cytogenetics. The karyotype of the leukemic cells is the strongest prognostic factor for response to induction therapy and for survival.36-37 Younger adult patients are commonly categorized into 3 risk groups, favorable, intermediate, or adverse.49-52 The most appropriate risk group assignment for a number of the rarer cytogenetic abnormalities, for example, del(7q), isolated trisomy 8, del(9q), t(v;11)(v;q23) other than t(9;11), and del(20q), remains uncertain due to limitations of sample size and differences in treatment schedule among studies. The impact of secondary genetic lesions in cases with balanced translocations or inversions requires further investigation.

Complex karyotype, which occurs in 10% to 12% of patients, has consistently been associated with a very poor outcome.55 Complex karyotype has been defined as the presence of 3 or more abnormal karyotypes.57-58 Complex karyotype has been proposed for elderly patients.61-63

Table 3. Test/procedures in the initial work-up of a patient with AML

<table>
<thead>
<tr>
<th>Test/procedure</th>
<th>General practice</th>
<th>Clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete blood counts and differential count</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Bone marrow aspirate</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Bone marrow trephine biopsy</td>
<td>Optional</td>
<td>Optional</td>
</tr>
<tr>
<td>Immunophenotyping</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Cytogenetics</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, or other gene fusion screening</td>
<td>Optional</td>
<td>Optional</td>
</tr>
</tbody>
</table>

Demographics and medical history* | Yes | Yes |
| Performance status (ECOG/WHO score) | Yes | Yes |
| Analysis of comorbidities | Yes | Yes |
| Biochemistry, coagulation tests, urine analysis | Yes | Yes |
| Serum pregnancy test† | Yes | Yes |
| Information on oocyte and sperm | cryopreservation | Optional | Optional |
| Eligibility assessment for autologous HSCT | Yes | Yes |
| Hepatitis A, B, C; HIV-1 testing | Yes | Yes |
| Chest x-ray, 12-lead ECG; echocardiography | (on indication) | Yes | Yes |
| Lumbar puncture‡ | No | No |
| Biobanking∥ | Optional | Yes |

**Prognostic/predictive marker assessment**

<table>
<thead>
<tr>
<th>Test/procedure</th>
<th>General practice</th>
<th>Clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPM1, CEBPA, FLT3 gene mutation</td>
<td>Optional</td>
<td>Yes</td>
</tr>
<tr>
<td>WT1, RUNX1, MLL, KIT, RAS, TP53, TET2, IDH1 gene mutation</td>
<td>No</td>
<td>Investigational</td>
</tr>
<tr>
<td>ERG, MN1, EVI1, BAALC gene expression</td>
<td>No</td>
<td>Investigational</td>
</tr>
<tr>
<td>Detection of minimal residual disease</td>
<td>No</td>
<td>Investigational</td>
</tr>
</tbody>
</table>

*Including race or ethnicity, family history, prior exposure to toxic agents, prior malignancy, therapy for prior malignancy, information on smoking.

†Biochemistry: glucose, sodium, potassium, calcium, creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, lactate dehydrogenase, bilirubin, urea, total protein, uric acid, total cholesterol, total triglycerides, creatine phosphokinase (CPK). Coagulation tests: prothrombin time (PTT), international normalized ratio (INR) where indicated, activated partial thromboplastin time (aPTT). Urine analysis: pH, glucose, erythrocytes, leukocytes, protein, nitrite.

‡Required in patients with clinical symptoms suspicious of central nervous system involvement; patient should be evaluated by imaging study for intracranial bleeding, leptomeningeal disease, and mass lesion; lumbar puncture considered optional in other settings (eg, high WBC).

∥Mandatory in patients with a dry tap (punctio sicca).

HLA typing and CMV testing should be performed in those patients eligible for allogeneic stem cell transplantation.

Biobanking should also be performed in general practice if at all possible.

MDS or MDS/MPN; therapy-related AML.), and performance status, older patients have worse outcomes than younger patients, suggesting the effect of unknown age-related factors. Nonetheless, calendar age alone should not be a reason for not offering potentially curative therapy to an older patient,46 because age is not the most important prognostic factor for either TRM or resistance to therapy. Attention should be given to a careful evaluation and documentation of comorbidities. In a recent study of patients older than 60 years of age receiving induction therapy (idarubicin 12 mg/m² for 3 days, cytarabine 1.5 g/m² for 3 days),47 scoring of baseline comorbidities using the hematopoietic cell transplantation comorbidity index (HCTCI)48 was predictive of early death rates and overall survival (OS). Comorbidity scoring is a current field of investigation and should contribute to a better definition of the patient considered “ unfit” for intensive chemotherapy.
consistently been shown for mutations in the *NPM1*, *CEBPA*, and *FLT3* genes alone or in combination in younger adult patients.

CN-AML patients harboring internal tandem duplication (ITD) of the *FLT3* gene have an inferior outcome compared with cases without *FLT3*-ITD.\(^6\) There is also evidence that outcome may be more related to the level of the mutated allele,\(^6,67,69,70\) rather than its mere presence, or to the insertion site of the ITD.\(^7\)\(^1\)\(^2\) The prognostic relevance of *FLT3* tyrosine kinase domain (TKD) mutations (at codons D835 and I836) remains controversial.\(^6,73,76\)

In several, but not all studies, the presence of *NPM1* mutation in CN-AML has been associated with higher CR rates and better RFS with mutations in *FLT3*-ITD represents a favorable prognostic marker, with higher CR rates, and better RFS and OS that is reminiscent of that seen in patients with inv(16) or t(8;21).\(^6,77-80\) This favorable impact of *FLT3*-ITD, and multiple studies have shown that the genotype “mutated *NPM1* without *FLT3*-ITD” represents a favorable prognostic marker, with higher CR rates, and better RFS and OS that is reminiscent of that seen in patients with mutant WT1.\(^81\)\(^-\)\(^84\) CN-AML patients harboring internal tandem duplication (ITD) of the *FLT3* gene have an inferior outcome compared with cases without WT1.\(^90\)\(^-\)\(^91\) It remains an open question whether the presence of a *FLT3*-ITD impacts on prognosis in patients with mutant *CEBPA*.\(^6,92\) In cytogenetically favorable CBF AML, the presence of a *KIT* mutation has been shown to have an unfavorable influence on outcome in retrospective studies.\(^93\)\(^-\)\(^97\)

There is a growing list of genetic abnormalities that are being investigated (Table 3). These include mutation analyses of the WT1,\(^98\)\(^99\) RUNX1,\(^100\) TET2,\(^101\)\(^102\)\(^103\) and IDH1 genes,\(^104\)\(^105\)\(^106\) and the analyses of gene expression signatures,\(^37,38\) or of deregulated expression of single genes, such as *EVII*,\(^19\) *ERG*,\(^104\) *MNI*,\(^105,106\) and *BAALC*.\(^107\)

### 5.2.3 Monitoring of minimal residual disease.

The monitoring of MRD as determined by RT-PCR detecting leukemia-specific targets (eg, gene fusions, gene mutations, overexpressed genes), or by multiparameter flow cytometry identifying leukemia-associated aberrant phenotypes remains an active field of investigation.\(^108\) Despite technical developments, there is still, except for APL,\(^4\) a paucity of large prospective trials demonstrating its clinical utility.\(^108\) Potentially useful applications of MRD monitoring include early assessment of response to therapy to improve risk stratification and guide postremission therapy; and posttreatment monitoring to detect impending relapse and guide preemptive therapy. The kinetics of RUNX1-RUNXIT1 and CBF-BMYH11 decline has been found to correlate with risk of relapse, or to represent a prognostic factor independent of other pretreatment variables.\(^108\)\(^-\)\(^110\) After consolidation therapy, low-level PCR-positivity can be detected in patients even in long-term remission of CBF AML. Normalizing to 10\(^6\) copies of *ABL1* in accordance with standardized criteria, transcript levels below 12 to 10 copies appear to predict long-term remission.\(^108\)\(^110\) Real-time quantitative (RQ)–PCR assays have been developed for other fusion gene targets such as *MLL* and *DEK*-NUMP214, but data are very scarce due to the low frequencies of these leukemias.\(^108\) *NPM1* mutations likely provide one of the most promising new targets and studies are ongoing to evaluate the clinical utility of MRD monitoring in AML with *NPM1* mutation.\(^111\)

The major advantage of using flow cytometric detection of MRD lies in its applicability to virtually all patients. Although its sensitivity, as reported in previous studies, is at least 1 log below that of RQ-PCR assays, the sensitivity will likely be improved by the use of 6- to 8-color laser technology. Among 8 studies,\(^108\) 7 demonstrated that immunophenotypic detection of MRD in AML after induction and consolidation provides independent prognostic information. Validation, using larger patient cohorts and modern technology, is ongoing.

---

**Figure 1.** Pie chart illustrating the molecular heterogeneity of cytogenetically normal AML based on mutations in the *NPM1*, *CEBPA*, *MLL*, *FLT3* (ITD and TKD mutations at codons D835 and I836), *NRAS*, and *WT1* genes. The bluish colors denote *NPM1*-mutated subsets, the orange/red colors *CEBPA*-mutated subsets, and the yellow/green colors *MLL*-mutated subsets. The gray colors depict subsets without hypothetical class II mutations, and the white sector shows the subset without mutation in the above-mentioned genes. Data are derived from mutational analysis of 485 younger adult patients with cytogenetically normal AML from AMLSG.
5.3 Standardized reporting system for genetic abnormalities

The panel proposes a standardized reporting system for genetic abnormalities when presenting data correlating genetic findings with clinical outcome allowing for a better comparison of data among studies (Table 4). This standardized report includes data from cytogenetic analysis and from mutation analyses of the NPM1, CEBPA, and FLT3 genes.

6. Response criteria and survival outcomes

Most response criteria and survival measures as described in the previous recommendations have been widely used by clinicians and cooperative groups (for definitions see Tables 5 and 6). Response criteria should meet the specific objective of a study, for example, in phase 2 and 3 clinical trials CR or CR with incomplete blood recovery (Cri) should be the appropriate end point, whereas in phase 1 clinical trials, the criteria of partial remission (PR) and morphologic leukemia-free state may also be useful. Other response criteria are cytogenetic CR (CRc)112-115 and molecular CR (CRm; Table 5).

Response assessment. After conventional induction therapy with 3 days of an anthracycline and 7 days of cytarabine (“3 + 7”) or therapies of comparable intensity, response assessment is commonly performed between day 21 and day 28 after start of therapy. The exact timing may vary among protocols and should meet the specific objectives of the study.

Table 5. Response criteria in AML

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete remission (CR)*</td>
<td>Bone marrow blasts &lt; 5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt; 1.0 x 10^9/L (1000/μL); platelet count &gt; 100 x 10^9/L (100 000/μL); independence of red cell transfusions</td>
</tr>
<tr>
<td>CR with incomplete recovery (CRI)†</td>
<td>All CR criteria except for residual neutropenia (&lt; 1.0 x 10^9/L [1000/μL]) or thrombocytopenia (&lt; 100 x 10^9/L [100 000/μL])</td>
</tr>
<tr>
<td>Morphologic leukemia-free state‡</td>
<td>Bone marrow blasts &lt; 5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required</td>
</tr>
<tr>
<td>Partial remission (PR)</td>
<td>Relevant in the setting of phase 1 and 2 clinical trials only; all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%</td>
</tr>
<tr>
<td>Cytogenetic CR (CRc)§</td>
<td>Reversion to a normal karyotype at the time of morphologic CR (or Cri) in cases with an abnormal karyotype at the time of diagnosis; based on the evaluation of 20 metaphase cells from bone marrow</td>
</tr>
<tr>
<td>Molecular CR (CRm)</td>
<td>No standard definition; depends on molecular target</td>
</tr>
<tr>
<td>Treatment failure</td>
<td>Resistant disease (RD) Failure to achieve CR or CRI (general practice; phase 2/3 trials), or failure to achieve CR, CRI, or PR (phase 1 trials); only includes patients surviving ≥ 7 days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination</td>
</tr>
<tr>
<td>Death in aplasia</td>
<td>Deaths occurring ≥ 7 days following completion of initial treatment while cytopenic; with an aplastic or hypocellular bone marrow obtained within 7 days of death, without evidence of persistent leukemia</td>
</tr>
<tr>
<td>Death from indeterminate cause</td>
<td>Deaths occurring before completion of therapy, or &lt; 7 days following its completion; or deaths occurring ≥ 7 days following completion of initial therapy with no blasts in the blood, but no bone marrow examination available</td>
</tr>
<tr>
<td>Relapse¶</td>
<td>Bone marrow blasts ≥ 5%; or reappearance of blasts in the blood; or development of extramedullary disease</td>
</tr>
</tbody>
</table>

Definitions of response criteria are based primarily on those given by Cheson et al.2

*All criteria need to be fulfilled; marrow evaluation should be based on a count of 200 nucleated cells in an aspirate with spicules; if ambiguous, consider repeat exam after 5 to 7 days; flow cytometric evaluation may help to distinguish between persistent leukemia and regenerating normal marrow; a marrow biopsy should be performed in cases of dry tap, or if no spicules are obtained; no minimum duration of response required.

†The criterion of CRI is of value in protocols using intensified induction or double induction strategies, in which hematologic recovery is not awaited, but intensive therapy will be continued. In such protocols, CR may even not be achieved in the course of the entire treatment plan. In these instances, the overall remission rate should include CR and CRI patients. Some patients may not achieve complete hematologic recovery upon longer observation times.

‡This category may be useful in the clinical development of novel agents within phase 1 clinical trials, in which a transient morphologic leukemia-free state may be achieved at the time of early response assessment.

§Four studies showed that failure to convert to a normal karyotype at the time of CR predicts inferior outcome.112-115

¶As an example, in CBF AML, low-level PCR-positivity can be detected in patients even in long-term remission. Normalizing to 10^4 copies of ABL1 in accordance with standardized criteria, transcript levels below 12 to 10 copies appear to be predictive for long-term remission.116-119

In cases with low blast percentages (5-10%), a repeat marrow should be performed to confirm relapse. Appearance of new dysplastic changes should be closely monitored for emerging relapse. In a patient who has been recently treated, dysplasia or a transient increase in blasts may reflect a chemotherapy effect and recovery of hematopoiesis. Cytogenetics should be tested to distinguish true relapse from therapy-related MDS/AML.
Blood counts should be done every 1 to 3 months for patients not known to have died at last follow-up, as are censored on the date they were last known to be alive.

Outside clinical trials, repeat marrow aspirates may be performed every 3 months for the first 2 years; in some cases, standardized time points are necessary if MRD monitoring is performed. Within clinical trials, it is usually recommended that repeat marrow aspirates be performed every 3 months for the first 2 years; in some cases, surveillance continues every 6 months for the following 2 to 3 years. Most relapses occur within 1 to 3 years after the end of therapy. Standardized time points are necessary if MRD monitoring is performed. Outside clinical trials, repeat marrow aspirates may not be needed, and should be done only if blood counts become abnormal. Blood counts should be done every 1 to 3 months for the first 2 years, then every 3 to 6 months up to 5 years.

7. Management of younger adults: 18 to 60 years

7.1 Induction therapy

Three days of an anthracycline (eg, daunorubicin, at least 60 mg/m² [higher doses are being explored], idarubicin, 10-12 mg/m², or the anthrancenedione mitoxantrone, 10-12 mg/m²) and 7 days of cytarabine (100-200 mg/m² continuous IV) (“3 + 7”) currently remains the standard for induction therapy. With such regimens, CR is achieved in 60% to 80% of younger adults. No other intervention has been convincingly shown to be better. Induction chemotherapy should be started after the diagnostic work-up has been completed, preferably with minimal delay. Retrospective data suggest that treatment outcome might be adversely impacted when the time from diagnosis to start of treatment increases beyond 5 days.

Alternative anthracyclines, high-dose cytarabine, additional agents given with conventional induction chemotherapy. Randomized studies have compared daunorubicin at a dose of 45-60 mg/m² with other anthracyclines, such as idarubicin or aclacinomycin, with anthrancenedione mitoxantrone, or with mitoxantrone. With respect to OS, it is not clear whether any agent is superior to daunorubicin at equivalent doses. High-dose cytarabine (HiDAC) combined with daunorubicin in induction has been studied by the Southwest Oncology Group (SWOG; 2 g/m² every 12 hours [q12h] on days 1-6), and the Australian Leukemia Study Group (ALSG; 3 g/m² per q12h on days 1, 3, 5, and 7) in prospective randomized trials, and by the Eastern Cooperative Oncology Group (ECOG; 3 g/m² per q12h on days 1, 3, and 5) and SWOG (cytarabine 100 mg/m² cont. IV on days 1-7, followed by HiDAC 2 g/m² per q12h on days 8-10; “3 + 7 + 3”) in phase 2 trials. Neither randomized trial showed a higher CR rate with HiDAC, and both demonstrated increased toxicity. In a trial by the AML Cooperative Group (AMLCG), 1 versus 2 courses with HiDAC (3 g/m² per q12h on days 1-3) in induction produced equal CR rates, disease-free survival (DFS) and moderate toxicity. Therefore, it is not generally recommended that HiDAC be included in induction regimens outside clinical trials.

Attempts to increase response rates by the use of additional cytotoxic agents (thioguanine, etoposide, fludarabine, topotecan), or modulators of multidrug resistance (MDR) in general have failed. Sensitization of leukemic cells with hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage (GM-CSF), has been studied to increase cytotoxicity of chemotherapy, and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) showed priming with G-CSF resulted in a significantly better DFS, and in the intermediate-risk group also a significantly better OS. Similarly, in a study by the Acute Leukemia French Association (ALFA) group, priming with GM-CSF resulted in a higher CR rate and a better EFS, in particular in the intermediate-risk group, albeit without influencing OS. In contrast, in a study by the AMLCG, G-CSF priming did not impact OS or DFS. Priming with growth factors remains an active field of clinical investigation; it cannot be recommended in routine practice. Another area of induction therapy research is the evaluation of gemtuzumab ozogamicin (GO) administered with conventional chemotherapy (see section 11.1).

7.2 Postremission therapy

7.2.1 Postremission strategies. Various types of postremission strategies have been evaluated including intensive conventional chemotherapy, prolonged maintenance treatment, and high-dose therapy followed by autologous or allogeneic hematopoietic stem cell transplantation (HSCT). A landmark study performed by Cancer and Leukemia Group B (CALGB) showed that 4 cycles of HiDAC (3 g/m² per q12h on days 1, 3, and 5) are superior to 4 courses of conventional chemotherapy (see section 11.2).
intermediate- (400 mg/m² continuous IV on days 1-5) or standard-dose (100 mg/m² continuous IV on days 1-5) cytarabine; patients were scheduled to also receive 4 courses of monthly maintenance treatment. This beneficial effect of cytarabine dose intensification, however, was restricted to patients with CBF AML and, to a lesser extent, to patients with CN-AML, whereas outcome of patients with other cytogenetic abnormalities was not affected by cytarabine dose. There remain open questions regarding the number of cycles, the most appropriate dose and schedule, and the role of combining HiDAC with other agents. Outcome results similar to those after HiDAC consolidation may be obtained using other intense chemotherapy regimens. However, use of prolonged intensive consolidation, or of multitarget chemotherapy does not appear to be superior to HiDAC alone.

Maintenance therapy. In one study there was no benefit in remission duration or OS with 3 years of intensive maintenance compared with autologous HSCT as postremission therapy, whereas maintenance proved superior for DFS to 1 course of consolidation according to the sequential HiDAC and mitoxantrone (S-HAM) protocol (HiDAC 1g/m² per q12h on days 1, 2, 8, and 9; mitoxantrone 10 mg/m² on days 3, 4, 10, and 11). Maintenance chemotherapy is generally not routinely administered outside of clinical trials for patients with non-APL AML.

Allogeneic hematopoietic stem cell transplantation. Allogeneic HSCT is considered an alternative option for postremission therapy in patients with favorable- and intermediate-risk cytogenetics, whereas it cannot be recommended in patients with high-risk cytogenetics. Outcome after autologous HSCT is at least as good as after the use of postremission chemotherapy; however, there has been no evidence of an improvement in outcome. Allogeneic HSCT may offer an advantage in specific subsets of AML.

Favorable-risk AML. Postremission therapy with repetitive cycles of HiDAC (3 g/m² per q12h on days 1, 3, and 5) is considered a reasonable choice for younger adult patients with CBF AML and, to a lesser extent, for patients with mutated NPM1 without FLT3-ITD and with mutated CEBPA. For CBF AML, retrospective studies by CALGB suggest that 3 or more cycles of HiDAC (cumulative dose: 54-72 g/m²) are superior to only one cycle (18 g/m²). No advantage has been shown for autologous or allogeneic HSCT in frontline treatment. Nonetheless, there are subsets of CBF AML that do rather poorly (eg, t(8;21) with high WBCs, CBF AML with KIT mutations or molecular disease persistence); allogeneic HSCT may be considered in these patients, especially for those with a low transplant risk (eg, European Bone Marrow Transplant [EBMT] risk 0-1, CMV-negative serostatus, no comorbidity), although such a strategy should be investigated within a clinical trial.

Intermediate-risk AML. For the remaining patients with CN-AML (intermediate-I) and those with intermediate-II karyotypes (Table 4), repetitive cycles of HiDAC (3-4 cycles; 3 g/m² per q12h on days 1, 3, and 5) are currently widely used by many cooperative groups; however, outcome for most of the subsets remains unsatisfactory. There is accumulating evidence that allogeneic HSCT is an attractive option for those patients who are at high risk of relapse. The benefit might be highest for patients with a low or intermediate transplant risk. A beneficial effect has been shown for patients with intermediate-risk cytogenetics in general, and for patients with CN-AML and unfavorable molecular markers, that is, those who lack the favorable genotypes of mutated NPM1 without FLT3-ITD or mutated CEBPA. In particular, although evidence from prospective trials is not available, allogeneic HSCT should be considered in patients whose leukemic cells have FLT3-ITD.

Adverse-risk AML. For most patients with high-risk cytogenetics, outcome remains dismal with conventional consolidation therapy. An allogeneic HSCT from a matched related donor is currently considered the treatment of choice for patients with unfavorable cytogenetics in CR1; this recommendation is based on results from single studies as well as from meta-analyses. The US Intergroup Study demonstrated an advantage for allogeneic HSCT for patients with unfavorable cytogenetics with a survival of 44% versus 15% for patients receiving only a single cycle of HiDAC consolidation chemotherapy, although the number of patients was small and the consolidation limited. Data from the European Organization for Research and Treatment of
Cancer (EORTC)/Gruppo Italiano Malattie Ematologiche d’Adulto (GIMEMA) AML-10 trial and from 3 consecutive trials of the HOVON-SAKK group with a larger number of patients demonstrate a benefit for allogeneic HSCT, among younger patients with adverse cytogenetics.155,156

The outcome after allogeneic HSCT from fully matched unrelated donors (defined by molecular high-resolution HLA typing) appears to be similar compared with allogeneic HSCT from matched related donors. The Center for International Blood and Marrow Transplant Research (CIBMTR) recently reported a long-term survival probability of 30% for AML patients with adverse cytogenetics transplanted in CR1 from matched unrelated donors.157 Given the dismal results after conventional chemotherapy, allogeneic HSCT from either matched related or unrelated donors in CR1 is therefore considered a reasonable treatment option for patients with unfavorable cytogenetics.

7.3 Primary refractory disease

Several studies have shown that lack of early blast clearance or nonresponse to the first induction cycle are major predictors for poor outcome, and conventional chemotherapy offers almost no chance of cure for these patients.148,173,174 Consequently, allogeneic HSCT has been widely used for these patients. Retrospective studies show outcome is limited by a high relapse rate and a high nonrelapse mortality leading to OS rates of 20% to 30%.175-179 To improve on these results, alternative conditioning regimens are being investigated. One approach evaluated in a multicenter trial is a sequential strategy of intensive chemotherapy followed, after 3 days of rest, by RIC for allogeneic HSCT, and prophylactic administration of donor lymphocyte infusions.180 A prerequisite for success for such a transplant strategy is rapid identification of a suitable matched donor. HiDAC, if not used for first induction, with or without an anthracycline may be considered for salvage therapy before allogeneic HSCT. Patients with induction failure who are not eligible for allogeneic HSCT should be considered for clinical trials evaluating novel agents.

8. Management of older patients: 60 years or older

Although the prognosis of AML probably worsens with each year of increasing age, “older” patients are generally considered those 60 or older. Older patients are more likely to suffer treatment-related early death and to exhibit therapeutic resistance.45,46,181 Increasing age is associated with factors predictive of early death, for example, poor performance status or various comorbidities, and of treatment resistance, for example, adverse cytogenetics, secondary AML, or the MDR phenotype.45,59-61 Even after accounting for these associations, older age remains an important predictor of poor outcome.45,46,83,182 Evidence is accumulating to indicate that in older patients age-dependent leukemia-specific differences also account for reduced treatment response.52 Older age per se, however, should not be a reason to withhold intensive therapy. Studies suggest that remission induction chemotherapy provides better quality of life and longer survival than supportive care only.46,183,184 Thus, these patients often deserve being offered the option of standard chemotherapy. Older patients from a clinical practice perspective may be divided according to whether they are 60 to 74, or 75 years of age or older.

8.1 Patients age 60 to 74

Induction therapy. For patients with performance status less than 2 and no comorbidities, standard induction therapy is often a plausible option resulting in CR rates averaging 50% and rates of death in aplasia or from indeterminate cause below 15%.45,181 Similar to younger adults, induction therapy generally consists of 3 days of an anthracycline (eg, daunorubicin 45-60 mg/m² or an alternative anthracycline at equivalent dose), and 7 days of cytarabine (100-200 mg/m² continuous IV). Dose reduction may be considered for individual patients. Both American185,186 and European187 cooperative group studies have found that the choice of anthracycline (daunorubicin or idarubicin, or the anthracyclene mitoxantrone) is of little consequence, assuming equitoxic doses are administered. The AMLCG over 15 years has used 60 mg/m² daunorubicin with acceptable toxicity.147 The HOVON/SAKK/ AMLSG recently showed that daunorubicin can be dose-intensified to 3 × 90 mg/m² in older patients up to 65 years with more CRs and better survival, without marked additional toxicity.188

The degree of acceptability of administering standard induction therapy depends greatly on cytogenetics. Adverse cytogenetics is a strong independent prognostic factor for failure to achieve CR and OS.61,62 For this subset of older patients, CR rates are 30% or less, and OS is less than 5%. Thus, although the karyotype may be unknown at diagnosis in most centers, patients known to have adverse cytogenetics, even those with a good performance status and lacking comorbidities, may be considered for investigational therapies, or, if such therapies are unavailable, for mild cytotherapeutic only. Recent data suggest delays in initiating therapy may not be harmful in older patients, thus allowing individualized approaches.119

Postremission therapy. Randomized studies in elderly patients achieving CR are biased because only a low proportion of the initial study cohort is randomized and the majority of these patients have intermediate- or favorable-risk cytogenetics and lack significant comorbidities. These studies have generally compared “more” versus “less” postremission therapy. In the British Medical Research Council (MRC) AML11 study, 4 postremission courses of moderate intensity were compared with 1 course, with equivalent survival in the 2 arms.189 The CALGB compared 2 relatively intense cycles (cytarabine 500 mg/m² per q12h; mitoxantrone 5 mg/m² per q12h, each for 6 doses) with 4 less intensive cycles (cytarabine 100 mg/m² continuous IV on days 1-3) and found no differences.190 In the AMLCG92 trial, older patients benefited with longer remission duration from monthly myelosuppressive maintenance (cytarabine 100 mg/m² per q12h × 10 with an anthracycline or thioguanine) compared with a single course of the S-HAM regimen (cytarabine dosage: 500 mg/m² per q12h on days 1, 2, 8, and 9).147 The French ALFA 9803 trial found that 6 cycles of outpatient consolidation (daunorubicin 45 mg/m² or idarubicin 9 mg/m² on day 1 and cytarabine 60 mg/m² per q12h) subcutaneously [s.c.] on days 1-5) gave superior DFS and OS than 1 cycle of “4 + 7” consolidation.187 Despite its longer duration, the outpatient arm required less time in hospital and fewer red cell and platelet transfusions. In the AMLSG AML HD98B trial, intensive consolidation (idarubicin 12 mg/m² on days 1 and 3; etoposide 100 mg/m² on days 1-5) was superior to a mild 1-year oral maintenance therapy (idarubicin 5 mg per os (p.o.) on days 1, 4, 7, 10, and 13; etoposide 100 mg p.o. on days 1 and 13; q4 weeks).191 From these data no clear recommendation can be given. For patients without adverse cytogenetics, good performance status and no significant comorbidity, standard “3 + 7” induction followed by repetitive
cycles of modest dose consolidation may be an acceptable norm, with recent results from the Swedish National Registry suggesting that this approach is associated with longer survival than lower doses of similar therapy.46

There is growing evidence that AML with a favorable genetic profile, that is, CBF AML and AML with mutated NPM1 (with or without FLT3-ITD), may benefit from dose escalation during consolidation.61-63,81,84,108 A recent AMLSG study suggests that AML with mutated NPM1 without FLT3-ITD may benefit from the addition of all-trans retinoic acid to intensive induction and consolidation therapy, although this finding awaits confirmation by further studies.31,192

**Allogeneic HSCT using reduced-intensity conditioning.** Allogeneic HSCT in older patients has become an active promising field of investigation.193-201 Nonmyeloablative or RIC regimens have been developed to reduce TRM in older or medically less fit patients. A retrospective study from the Cooperative German Transplant Study Group of 368 patients (median age, 57 years; range, 50-73) suggests that matched unrelated and matched sibling donor allogeneic HSCT (72% had received RIC regimens) result in comparable survival in older AML patients.202

Nevertheless, current data are difficult to interpret due to small patient cohorts, heterogeneity of conditioning regimens applied, and, most importantly, the considerable inherent patient selection bias in the higher age segment.200 Therefore, allogeneic HSCT should be performed within clinical trials. A prospective comparison of allogeneic HSCT from matched related and unrelated donors using RIC with conventional consolidation therapy has been launched by the EBMT group together with several cooperative groups (ClinicalTrials.gov Identifier: NCT00766779).

**8.2 Patients age 75 or older**

An alternative to standard-dose induction should be sought for patients 75 or older (and probably ≥ 65) with a performance status of 2 or 3, comorbidities, or organ dysfunction. In a randomized trial,200 low-dose cytarabine (LDAC; 20 mg twice daily s.c. for 10 days) was associated with longer survival than hydroxyurea (sufficient dose to keep WBC < 10 x 109/L) and thus might be considered for such patients, but the magnitude of benefit is not so great as to make hydroxyurea or supportive care an unreasonable option. Even with this low-intensity approach, there was a 30-day mortality of 26%. Furthermore, there is no benefit of LDAC in patients with adverse cytogenetics.203,204 The choice of therapy very much depends on a patient’s wishes. Any discussion of choice of therapy must refer to observations that 74% of older patients estimated that their chances of cure with “3 + 7” were 50% or more; in contrast, 85% of their physicians estimated this chance to be less than 10%.205

For patients age 75 or older but with a good performance status and no comorbidities, selection of treatment may again be contingent on cytogenetics and to a lesser extent on type of AML (de novo vs secondary after MDS or MDS/MPN). Patients age 66 or older with CBF AML have a 75% CR rate and only a 16% death rate with cytarabine-containing therapy, making standard therapy a very plausible option.206 Furthermore, some such patients if particularly healthy might be candidates for more aggressive consolidation including moderate-dose cytarabine.61-63,81 Recent data suggest that patients age 60 or older with CN-AML and mutated NPM1 (with or without FLT3-ITD) benefit from standard “3 + 7” regimens.81,84

**8.3 Cautions and future directions**

Patients entered onto clinical trials of either standard or investigational therapy represent a very small, and likely biased, subset,207 and reported results overestimate the effectiveness of therapy in the general population of older AML.46,208 Physicians decide to give treatment to some patients but not others based on generally accurate perceptions of how patients will fare after such treatment,200 or on strict protocol exclusion criteria.200 Examining 2657 Medicare beneficiaries older than 65 in American Surveillance, Epidemiology, and End Results (SEER) registries, Menzin et al208 found that 70% did not receive “chemotherapy,” ranging from 56% of patients age 65 to 74, to 94% of patients age 85 or older. In the Swedish Adult Acute Leukemia Registry, a true population-based registry, 198 of 727 (27%) patients age 65 to 74 and 800 of 1 115 (72%) patients age older than 74 did not receive intensive chemotherapy but palliation only.46

A second problem is the heterogeneity present in any sizable defined group, but hidden by the terms “older patient,” “medically unfit patient,” or “patient ineligible for standard intensive chemotherapy.” Thus, there is a need to consider multiple variables. Besides age, the most important covariates are cytogenetics and secondary AML (following MDS or MDS/MPN), WBC, performance status, and comorbidities.209 No specific comorbidity index has yet been developed for older patients with AML; thus, only organ dysfunctions are currently taken into account.

As is apparent from the many new induction therapies being studied in older patients, it is easier to recognize that a patient needs investigational therapy than it is to specify what that therapy should be. Part of this difficulty reflects the tendency to report results of single-arm trials without reference to even a historical control group.210 Current examples of investigational therapies include clofarabine, cloretazine, azacitidine (or decitabine) ± histone deacetylase inhibitors or GO, “3 + 7” or LDAC combined with GO, and FLT3 inhibitors in patients with activating FLT3 mutations (see section 11). Tipifarnib has been compared with best supportive care in older patients and was found not beneficial.211

**9. Therapy-related AML**

Therapy-related AML (t-AML) is a recognized clinical syndrome occurring as a complication after cytotoxic and/or radiation therapy. With emerging new therapies, for example, treatment with monoclonal antibodies, small molecules, antihormone agents and growth factors, the term “t-AML” has blurred and its definition needs to be revisited. Therefore, it is important that previous therapies be meticulously documented and reported.

The etiology and specific factors that predispose to therapy-related myeloid neoplasms largely remain elusive.212,213 Various genetic pathways and cooperating mutations are involved in its pathogenesis.214 Two main groups have been described, one comprising leukemias arising 5 to 7 years after therapy with alkylating agents or irradiation and associated with abnormalities of chromosome arms 5q and/or 7q, and a second occurring with a shorter latency, within 2 to 3 years, after therapy with agents targeting topoisomerase II that are often associated with a translocation involving bands 11q23 (MLL) or 21q22 (RUNX1). However, there appear to be more pathways comprising chromosomal rearrangements and mutations in multiple genes (eg, TP53, RUNX1, RAS).214

Survival of t-AML patients has been poor compared with that of patients with de novo AML.212,215-22 Several factors may explain
the poor outcome, such as persistence of the primary malignant disease, injury to organs from prior therapy, depletion of normal hematopoietic stem cells, damage to narrow stroma (in particular by radiation therapy), chronic immunosuppression or dysfunctional phagocytes leading to colonization with pathogenic or antibiotic-resistant bacteria and fungi, and refractoriness to transfusion support. Finally, t-AML is associated with a higher frequency of unfavorable cytogenetics. In multivariable analyses, however, t-AML appears to remain an independent adverse prognostic factor. A recent study suggests that survival is also poorer in patients with therapy-related CBF-AML compared with de novo CBF-AML.

There is a paucity of prospective treatment data because patients with t-AML have often been excluded from frontline clinical trials. There are no randomized studies comparing standard AML therapy to other forms of treatment. In a review of 644 t-AML patients treated with various standard AML chemotherapy regimens, only 182 (28%) achieved a CR. Individual small series report CR rates of 40% to 50%. The treatment most likely to cure t-AML is allogeneic HSCT. In case series, OS appears to be approximately 20% to 30%. Nonmyeloablative, RIC allogeneic HSCT is under investigation for those who are not eligible for standard myeloablative HSCT. The EBMT Registry reported on 65 t-AML patients who underwent autologous HSCT; the 3-year OS was 35%.

Thus, primary considerations for treatment of t-AML patients should include the status of the primary cancer, the patient’s performance status, the presence of complications from primary therapy, and the leukemic karyotype. Patients with t-AML should be encouraged to participate in prospective trials that are designed for other AML patients with similar genetic changes. Patients who have an HLA-matched donor should be considered for allogeneic HSCT.

### 10. Relapsed AML

In the majority of patients with AML who achieve a CR, the leukemia will recur within 3 years after diagnosis. In general, the prognosis of patients after relapse is poor and treatment options unsatisfactory.

#### 10.1 Prognostic factors in relapsed AML

Because of the poor prognosis of patients in relapse, it would be useful to be able to assess whether treatment with curative intent is a realistic possibility for a particular patient. Long-term survival will depend on the ability to successfully induce a remission and the probability to consolidate with HSCT. Patients with an early relapse (ie, duration of CR1 < 6 months), adverse cytogenetics, or older age have a poor outcome. An estimate of long-term survival can be obtained by assessing a defined set of prognostic factors as shown in Table 7. The prognostic score furnishes a basis for recommendations regarding treatment with curative objectives, or palliative therapy, or therapy in the context of a phase 1/2 study.

#### 10.2 Reinduction of remission

There is a lack of prospective controlled studies evaluating different treatments in relapsed AML, and therefore no generally established standard. A commonly accepted approach is to define a treatment that is directed at achieving a new remission and that leads to HSCT. One mainstay of second-line treatment is cytarabine which can be used at intermediate (1 g/m²) and high-dose (2-3 g/m²) levels. An example of a salvage regimen is cytarabine (3 g/m² per q12h on days 1, 3, 5, and 7) combined with daunorubicin (50 mg/m²) or idarubicin (10 mg/m²) on days 2, 4, and 6. Another schedule is single agent cytarabine for 6 days (2-3 g/m² per q12h). Regimens that include cytarabine at high doses cannot be safely applied in patients aged 60 years or older because of an unacceptably high risk of toxicity. Another schedule is mitoxantrone (10 mg/m² per day) and etoposide (100 mg/m² per day) given for 5 days. GO (see section 11.1) can produce remissions in older patients, especially those relapsing after a prolonged (> 6 months) CR1. Patients with short initial first remissions may be candidates for an investigational drug.

#### 10.3 Salvage consolidation treatment including stem cell transplantation

Allogeneic HSCT is the preferred consolidation therapy once a new remission has been attained. This can be a transplant from an HLA identical sibling donor, or a matched unrelated donor. If such a donor is not available, an alternative donor can be considered, that is, an umbilical cord blood unit, or a haploidentical donor. In this situation, the risk of the disease has to be balanced with the risk of the transplant. The long-term value of allogeneic HSCT after RIC regimens remains to be evaluated but current experience suggests a greater relapse incidence compared with transplants after high-dose preparative regimens. If an allogeneic HSCT is not possible (eg, due to lack of a suitable donor), an autologous HSCT is often regarded as the second best option. However, often it is not possible to collect an adequate leukemia-free autograft at this phase of the disease. Retrospective studies show that patients who achieve second CR and proceed to autologous HSCT have a probability of long-term survival in the range of 20% to 50%. The outcome obviously applies to a highly selected minority of patients. Patients who have already undergone an allogeneic HSCT before relapse generally have immunophrophylaxis discontinued, and may receive donor lymphocyte infusions. These interventions are not an option in patients who already have active graft-versus-host disease (GVHD). Finally, transplant recipients with a late relapse (> 1 year after allogeneic HSCT) may be offered a second transplant.

---

**Table 7. Prognostic index for younger adults with AML in relapse**

<table>
<thead>
<tr>
<th>Risk</th>
<th>Index score in points</th>
<th>Survival probability, % at 1 y</th>
<th>Survival probability, % at 5 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable (9% of patients)</td>
<td>0-6</td>
<td>70</td>
<td>46</td>
</tr>
<tr>
<td>Intermediate (25% of patients)</td>
<td>7-9</td>
<td>49</td>
<td>18</td>
</tr>
<tr>
<td>Unfavorable (66% of patients)</td>
<td>10-14</td>
<td>16</td>
<td>4</td>
</tr>
</tbody>
</table>

Evaluated in patients 15 to 60 years old, APL with t(15;17) excluded; prognostic relapse score is estimated according to the following factors:

- Duration of remission prior to relapse: > 18 months (0 points); 7 to 18 months (3 points); and 6 months or less (5 points).
- Cytogenetics at initial diagnosis: inv(16) or t(16;16) (0 points); t(8;21) (3 points); other (5 points).
- Prior hematopoietic stem cell transplantation: no (0 points); yes (2 points).
- Age at time of relapse: 35 years or less (0 points); 36 to 45 years (1 point); more than 45 years (2 points).
11. Molecularly targeted therapy

Progress has been made in deciphering the molecular pathogenesis of AML, and in a few instances this has led to the development of molecularly targeted approaches. Genetic alterations comprise mutations in genes that activate signal transduction cascades (eg, FLT3, KIT, RAS), gene fusions or mutations resulting in enhanced or repressed transcriptional activity (eg, PML-RARA, RUNX1-RUNXIT1, CBFB-MYH11, CEBPA), or altered function of genes involved in nuclear cytoplasmic shuttling (eg, NPM1, NUP98, NUP214). Inhibition of deregulated transcriptional activity has, with the exception of the use of all-trans retinoic acid and arsenic trioxide in APL, proved to be a less tractable pharmacologic goal compared with inhibition of constitutive tyrosine kinase activity. Finally, targeting the myeloid-associated antigen CD33 by the use of anti-CD33 monoclonal antibody has become an interesting new approach.

It is commonly accepted that the AML phenotype results from multiple genetic/epigenetic lesions affecting differentiation, proliferation, and apoptosis. Consequently, targeting of a single aberrant protein is unlikely to eradicate the leukemic clone. Furthermore, although several molecularly targeted therapies have been shown to be active in AML, it is clear from early clinical studies that most of these novel agents will need to be used in combination with conventional cytotoxic therapy. In the following sections, only 3 modalities are considered that have reached phase 3 clinical trial development for frontline therapy of AML.

11.1 Gemtuzumab ozogamicin

GO is a humanized anti-CD33 antibody chemically linked to the cytotoxic agent calicheamicin that inhibits DNA synthesis and induces apoptosis.247-249 GO is approved for relapsed AML (currently in the United States and Japan, but not in Europe) in older patients who are not considered candidates for other cytotoxic therapies.249 GO can produce remissions in 15% to 35% of older patients in first relapse. In a feasibility study in younger adults, the addition of GO to standard induction therapy led to a promising 91% CR rate.250 Randomized trials evaluating the addition of GO to conventional chemotherapy have been completed (eg, MRC AML 15 trial; final results are pending) or are ongoing (eg, SWOG Protocol S0106; ClinicalTrials.gov Identifier: NCT00085709).

11.2 FLT3 inhibitors

Several FLT3-selective tyrosine kinase inhibitors (eg, midostaurin [PKC412],251 lestaurtinib [CEP-701],252 sunitinib [SU11248]253) have in vitro cytotoxicity to leukemia cells. These inhibitors have activity as a single agent in relapsed AML with FLT3 mutations, although usually only a transient reduction of blasts in blood, and, to a lesser extent, in marrow, has been observed.254-256 Pilot studies combining intensive induction and consolidation therapy with FLT3 inhibitors have shown promising response rates in patients with FLT3 mutations. A randomized phase 3 trial has been initiated evaluating midostaurin as frontline therapy of younger adult AML patients with activating FLT3 mutations (ClinicalTrials.gov Identifier: NCT00651261).

11.3 Demethylating agents

Two demethylating agents, the cytosine analogs azacitidine and decitabine,257-259 have been approved for the treatment of MDS, azacitidine by the Food and Drug Administration (FDA) and the European Medicine Agency (EMEA) and decitabine by the FDA. In a phase 3 randomized trial, azacitidine prolonged OS compared with conventional care regimens in patients with intermediate-2 or high-risk MDS.260 Approximately one-third of these patients (n = 113) were classified as having AML under current WHO criteria (blast counts 20%-30%). Of note, in these patients, the 2-year OS was 50% with azacitidine compared with 16% with conventional treatment regimens.261 Based on these results, azacitidine has been approved for older AML with 20% to 30% blasts. While these results are promising, data for more proliferative AML are currently not available. Randomized trials comparing demethylating agents with conventional cytotoxic agents in older AML patients with blast percentages more than 30% are underway.

12. Management of special situations

12.1 Hyperleukocytosis

Hyperleukocytosis, generally defined as a WBC more than 100 × 10^9/L, is associated with increased induction mortality mainly due to hemorrhagic events, tumor lysis syndrome, and infections.262 Hyperleukocytosis with leukostasis and, for example, pulmonary infiltrates or retinal and cerebral hemorrhages requires immediate medical treatment. Leukapheresis is an option for the initial management of hyperleukocytosis; however, no impact on long-term outcome has been shown.263,264 In general, the recommended therapy to lower WBC is hydroxyurea, given at dosages up to 50 to 60 mg/kg per day, until WBCs are less than 10-20 × 10^9/L. Until the WBC has been reduced, excessive red blood cell transfusions can lead to increased blood viscosity. Special attention should be given to the prevention of tumor lysis syndrome (eg, hydration, control of uric acid production using allopurinol or rasburicase, control of urine pH).

12.2 Central nervous system involvement

Initial involvement of the central nervous system (CNS) in AML occurs in less than 5% of patients.265 There is no indication for intrathecal prophylaxis in patients without CNS symptoms,265 although it may be considered in special situations (eg, hyperleukocytosis).

In patients with CNS involvement, 40 to 50 mg of cytarabine should be administered intrathecally, 2 to 3 times per week until clearance of blasts, followed by 3 further injections with the same dosage. Alternatively, liposomal cytarabine (50 mg every other week) may be given for approximately 6 cycles. For prevention of arachnoiditis, dexamethasone (4 mg three times a day [tid] p.o.) may be considered on the days of intrathecal application. Prolonged application of intrathecal therapy does not appear to be justified, given that such therapy carries the risk of complications (eg, leukencephalopathy). In patients with a CNS recurrence, craniospinal irradiation with or without intrathecal chemotherapy has also been shown to be effective; however, its impact on long-term outcome is unknown.267

12.3 Myeloid sarcoma

Myeloid sarcoma (synonyms: extramedullary myeloid tumor, granulocytic sarcoma, chloroma) is a tumor mass consisting of myeloid blasts in which the tissue architecture is effaced, occurring at an anatomical site other than the bone marrow,3 most commonly in skin, lymph nodes, gastrointestinal tract, bone, soft tissue, and
testis. Myeloid sarcoma may present de novo preceding AML, concurrently with AML, or as blastic transformation of MDS, MPN, or MDS/MPN. Diagnosis is ascertained by cytochemical and/or immunohistochemical analyses. Often myeloid sarcomas have myelomonocytic or monoblastic morphology. Myeloid sarcomas should be evaluated for genetic and phenotypic features that allow for their classification in the appropriate WHO entity. Myeloid sarcomas have been associated with hyperleukocytosis, t(8;21), and CD56 positivity.268,269

Myeloid sarcoma occurring de novo should be considered as AML and treated as such. Data on the prognostic impact of myeloid sarcoma are limited. Whereas some studies reported a negative impact in selected subgroups,269,270 others suggest that outcome of patients with myeloid sarcoma after conventional chemotherapy or allogeneic HSCT may not be inferior.271,272 Involved field radiation therapy may be considered to enhance local tumor control.

12.4 Pregnancy

Acute leukemia during pregnancy should be managed jointly by the hematologist, obstetrician, and neonatologist. Consideration must be given to both the health of the mother and to the immediate as well as long-term consequences for the fetus exposed to cytotoxic agents. Pregnancy does not appear to alter the course of AML, with more than 75% of patients achieving CR after standard chemotherapy.273-275 Treatment should be started immediately because delays may compromise maternal outcome.274

Leukemia in a pregnant woman bears an increased risk for abortion, intrauterine growth restriction, and perinatal mortality.276-278 The earlier in gestation the diagnosis of leukemia, the higher the incidence of spontaneous abortion, prematurity, and low birthweight. The risk of teratogenicity is highest during weeks 2 to 8 after conception, the period of organogenesis.278 Malformations after exposure to anthracyclines and cytarabine in the first trimester have been reported.278 Idarubicin differs from the other anthracyclines because it is more lipophilic favoring an increased placental transfer and has a higher DNA affinity; thus, daunorubicin should be given rather than idarubicin.279 Given the risk of teratogenicity, the option of therapeutic termination during the first trimester of pregnancy should be submitted for consideration by the mother. Chemotherapy delivered during the second and third trimester of pregnancy has been reported as safe, although stillbirths and low birthweight have also been observed.275,275-277 Delivery while patient and fetus may be cytopenic should be avoided.

13. Supportive care

13.1 Prophylactic anti-infectious treatment

For prophylaxis and treatment of infectious diseases, prevailing institutional infectious organisms and their drug-resistance pattern should primarily be considered. Personal hygiene, dental care, and vigorous hand washing (the latter also for family and caregivers) are very important for prevention of infections. Reasonable precautions should be undertaken to protect patients from bacteria or fungi in their environment. Although eating fresh fruits and/or vegetables is often discouraged, there is little evidence that adherence to such a “neutropenic diet” prevents infections.280

Fungal prophylaxis. Invasive fungal infections are a major cause of morbidity and mortality in patients with prolonged neutropenia.281 A review of randomized trials in AML found a significant reduction in fungal infection–related mortality and invasive fungal infection in patients given antifungal prophylaxis rather than placebo while the difference in all-cause mortality was borderline significant.282 Prophylaxis with itraconazole, posaconazole, or amphotericin, that is, drugs with antimold activity, reduced the risk of documented aspergillus infection and likely had some effect on mortality. A recent trial found that patients randomized to posaconazole had fewer invasive fungal infections than patients randomized to either fluconazole or itraconazole according to institutional practice.283 Survival was longer in the posaconazole group, although it is unclear how much of the difference was due to the superiority of posaconazole to itraconazole rather than the superiority of posaconazole to fluconazole. In addition, prophylaxis may not be as efficacious if other modes of prophylaxis are used, for example, high-efficiency particulate (HEPAR) air filtration. Nonetheless, the limited data suggest that patients should receive an antimold agent, rather than fluconazole, during remission induction therapy.

Antibiotic prophylaxis. Bacterial infections are an important cause of morbidity and mortality in neutropenic patients after chemotherapy for AML.284 A Cochrane review compared antibiotic prophylaxis with placebo or no intervention in afebrile neutropenic patients.285 Antibiotic prophylaxis significantly decreased the risk of death and the risk of infection-related death. The most significant reduction in risk for all-cause mortality was observed in trials testing prophylaxis with quinolones, despite the occurrence of adverse effects and development of resistance.286 Thus, antibiotic prophylaxis should be given after chemotherapy for AML with a preference for a quinolone.

13.2 Growth factors

Numerous studies138,185,287-303 have shown that myeloid growth factors, either GM-CSF or G-CSF, accelerate neutrophil recovery by 2 to 5 days, can reduce antibiotic use, duration of fever, and number of days spent in hospital, and do not retard platelet recovery, or have a detrimental effect by stimulation of leukemic cell growth. However, the use of growth factors does not translate into a survival benefit. The cost effectiveness of growth factors is difficult to assess and has been inconsistently reported, but there does not seem to be significant cost savings. Thus, the general use of growth factors in AML cannot be recommended. However, in individual cases (eg, severe infection before expected neutrophil recovery), growth factor use can be considered.

13.3 Transfusion support

Platelet transfusion. The introduction of platelet transfusions has dramatically reduced mortality from hemorrhage in AML.304 For many years, platelet transfusions were given to keep platelet counts above 20 × 10^9/L. However, in 3 randomized studies, no significant differences in severe bleeding were shown if a threshold of less than 10 × 10^9/L rather than less than 20 × 10^9/L for prophylactic platelet transfusion was used.305-307 American Society of Clinical Oncology guidelines recommend a threshold of 10 × 10^9/L for prophylactic platelet transfusions.308 Besides the platelet count, mucosal bleeding, infection, severe mucositis, and fever should be considered in the assessment of bleeding risk and should increase the transfusion threshold.
To prevent alloimmunization, removal of contaminating leukocytes is advised. Nevertheless, alloimmunization remains a major obstacle to effective transfusion due to antibodies to HLA class I antigens in many women with prior pregnancies or patients with prior transfusions.\(^{309}\) Such alloimmunized patients are transfused with either HLA-matched platelets or crossmatch- compatible platelets. Both are equally effective.\(^ {310}\) Although single-donor platelets are often thought preferable to platelets obtained from multiple donors, a randomized trial showed that they were no more effective in reducing alloimmunization or refractoriness to transfusions.\(^ {311}\) The antifibrinolytic agent tranexamic acid can be useful in reducing bleeding and platelet transfusion.\(^ {312}\) Anecdotal reports suggest a role for the use of recombinant human activated factor VII in the treatment of bleeding in AML patients refractory to platelet transfusions; however, well-designed clinical trials are lacking.\(^ {313}\)

**Red blood cell transfusion.** Although evidence is lacking, it is generally accepted to keep the hemoglobin level above 8 g/dL, especially in thrombocytopenic patients.

**Granulocyte transfusion.** No good evidence exists to recommend granulocyte transfusions in the treatment of AML. A multicenter randomized trial to address the utility of such transfusions in the setting of infections is being conducted in the United States (ClinicalTrials.gov Identifier: NCT00627393).

**Transfusion practice before, during and after HSCT.** Only leukocyte-depleted erythrocyte and platelet components should be given to decrease the risk of HLA-associated alloimmunization and reduce the risk of CMV transmission.\(^ {314}\) Both autologous and allogeneic stem cell recipients are at risk for transfusion-associated GVHD. Gamma irradiation (at least 25 Gy) is the only reliable method to prevent transfusion-associated GVHD. There is no general consensus when to begin with the transfusion of irradiated blood products. Commonly used practice is to transfuse irradiated blood products from start of conditioning until 6 months after transplant (in the absence of chronic GVHD; allogeneic HSCT), and from 7 days before stem cell harvest until 3 months post transplant for autologous HSCT. Some centers start as soon as a patient is identified to be a potential HSCT candidate. All CMV- seronegative HSCT recipients with seronegative donors should receive CMV-seronegative blood products.

**Acknowledgments**

We gratefully acknowledge Rüdiger Hehlmann for his generous support of the initiative on behalf of the European LeukemiaNet, Michael Borowitz for reviewing the section on immunophenotyping, and Krzysztof Mrózek and Alois Gratwohl for critically reviewing the manuscript.

This work was supported by the European Union, Sixth Framework Programme, contract no. LSHC-CT-2004-503216 (European LeukemiaNet).

**Authorship**

Contribution: All authors reviewed the literature and wrote first drafts of specific sections; H. Döhner and C.D.B. assembled the sections and wrote the final version of the manuscript; and all authors reviewed and approved the final version of the manuscript.

Conflict-of-interest disclosure: H. Döhner serves as a consultant to Celgene. A.K.B. receives research funding from Cephalon, Genzyme, Novartis, and Cyclacel. H. Dombret serves as a consultant to Genzyme, Celgene, Sanofi-Aventis, Chugai, Vion, and Bristol-Myers Squibb, and receives lecture fees from speaking at the invitation of sponsors Bristol-Myers Squibb, Celgene, Genzyme, Novartis, and GlaxoSmithKline. P.F. receives research funding from Amgen, Celgene, and Roche, and serves as a consultant to Celgene, Novartis, Merck, Ortho Biotech, Cephalon, and Amgen. R.A.L. receives research funding from Amgen, Bristol-Myers Squibb, Celgene, Novartis, Gemin X, Sanofi-Aventis, Chroma Therapeutics, and Ambit Biosciences, and serves as a consultant to Novartis, Hana Biosciences, Antisoma, Caremark, Trubion, and Celgene. J.S. receives research funding from Amgen, Celgene, and Novartis, and serves as a consultant to Wyeth and Genzyme. M.S.T. serves as a consultant to Genzyme. The remaining authors declare no competing financial interests.

Correspondence: Dr. Hartmut Döhner, Department of Internal Medicine III, University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany; e-mail: hartmut.dohner@uniklinik-ulm.de.

**References**


46. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds...


130. Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of ﬂudarabine and topotecan as induction therapy with standard daunorubicin and cytarabine fol-


132. Bishop JF, Lowenthal RM, Joshua D, et al. Etopo-

133. Hann IM, Stevens RF, Goldstone AH, et al. Randomi-
ized comparison of DAT versus ADE as in-

fractory anemia with excess blasts in transforma-


136. Büchner T, Hiddemann W, Berdel WE, et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitox-

antrone (HAM) for induction, for consolidation, and for primary refractoriness by re-
duced monthly HAM or HAD-HAM and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21(24):4496-4504.


138. Bremes DA, Löwenberg B. Acute myeloid leuke-
mia and the position of autologous stem cell transplan-

tive analysis of autologous bone marrow transplan-
tation and intensive chemotherapy as post-remis-


1656.


142. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplan-

111. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 muta-
tion speciﬁc PCR-RFLP provide important prognostic information in AML. Blood. 2009;114(11):2220-2231.

112. Freireich EJ, Cork A, Stass SA, et al. Cytogenet-

113. Grimmwade D, Walker H, Oliver F, et al. What hap-
rens subsequently in AML when cytogenetic ab-
normalities persist at bone marrow harvest? Re-

mal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leu-


116. Estey E, Pierce S. Routine bone marrow exam-

117. Löwenberg B, Griffin JD, Tallman MS. Acute my-
eloid leukemia and acute promyelocytic leuke-

118. Freireich EJ, Cork A, Stass SA, et al. Cytogenet-

119. Sekeres MA, Elson P, Kalaycio ME, et al. Time to diagnosis from treatment initiation predicts survival in younger, but not older, acute myeloid leu-

120. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubi-
icin in combination with cytarabine in acute my-

121. Wiernik PH, Banks PLC, Case DC Jr, et al. Cyta-
rabine plus idarubicin or daunorubicin as induction and consolidative therapy for previously un-
treated adult patients with acute myeloid leu-

122. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cyto-

ebine in previously untreated adult patients with newly diag-


ously untreated patients with acute myeloid leu-
kenia: a Danish national phase III trial. Leu-

125. Berman E, Arlin ZA, Gaynor J, et al. Compara-
tive trial of cytarabine and thioguanine in combination with amrsamine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia. 1989;3(2):115-

126. Arlin Z, Case DC Jr, Moore J, et al. Randomized multcenter trial of cytosine arabinoside with mi-
toxantrone or daunorubicin in previously un-


with previously untreated acute myeloid leuke-
mia: a Southwest Oncology Group study (9031).

299. Estey EH, Thall PF, Pierce S, et al. Randomized
phase II study of fludarabine + cytosine arabinos-
ide + idarubicin ± all-trans retinoic acid ±
granulocyte colony-stimulating factor in poor
prognosis newly diagnosed acute myeloid leuke-
mia and myelodysplastic syndrome. Blood. 1999;
93(8):2478-2484.

of glycosylated recombinant human granulocyte
colonystimulating factor after high-dose cytara-
bine-based induction chemotherapy for adult
acute myeloid leukaemia. Leukemia. 2001;15(9):
1331-1338.

granulocyte colony-stimulating factor in the treat-
ment of acute myelogenous leukaemia: a multi-
116(1):103-112.

302. Amadori S, Suciu S, Jehn U, et al. Use of glyco-
sylated recombinant human G-CSF (lenograstim)
during and/or after induction chemotherapy in
patients 61 years of age and older with acute my-
eloid leukemia: final results of AML-13, a random-

303. Sierra J, Szer J, Kassis J, et al. A single dose of
pegfilgrastim compared with daily filgrastim for
supporting neutrophil recovery in patients treated
for low-to-intermediate risk acute myeloid leuke-
mia: results from a randomized, double-blind,

304. Freireich EJ. Supportive care for patients with
77.

305. Heckman KD, Weiner GJ, Davis CS, Strauss RG,
Jones MP, Burns CP. Randomized study of pro-
phyllactic platelet transfusion threshold during in-
duction therapy for adult acute leukemia:
10,000/μL versus 20,000/μL. J Clin Oncol. 1997;

threshold for prophylactic platelet transfusions in
adults with acute myeloid leukemia. N Engl

A prospective randomized trial of prophylactic
platelet transfusion and bleeding incidence in he-
matopoietic stem cell transplant recipients:
10,000/μL versus 20,000/μL trigger. Biol Blood

Platelet transfusion for patients with cancer: clini-
cal practice guidelines of the American Society of
1538.

309. Densmore TL, Goodnough LT, Ali S, Dynis M,
Chaplin H. Prevalence of HLA sensitization in fe-
male apheresis donors. Transfusion. 1999;39(1):
103-106.

310. Rebull P. A mini-review on platelet refractori-

311. The Trial to Reduce Alloimmunization to Platelets
Study Group. Leukocyte reduction and ultraviolet
B irradiation of platelets to prevent alloimmuniza-
tion and refractoriness to platelet transfusions.

312. Shpilberg O, Blumenthal R, Sofer O, et al. A con-
trolled trial of tranexamic acid therapy for the re-
duction of bleeding during treatment of acute my-
141-144.

313. Poon MC. The evidence for the use of recombi-
nant human activated factor VII in the treatment
of bleeding patients with quantitative and qualita-
tive platelet disorders. Transfus Med Rev. 2007;
21(3):223-236.

314. Gajewski JL, Johnson VV, Sandler SG, Sayegh
A, Klimpp TR. A review of transfusion practice
before, during, and after hematopoietic progenitor
cell transplantation. Blood. 2008;112(8):3036-
3047.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet


Updated information and services can be found at: http://www.bloodjournal.org/content/115/3/453.full.html

Articles on similar topics can be found in the following Blood collections
- Free Research Articles (4685 articles)
- Myeloid Neoplasia (1730 articles)
- Review Articles (714 articles)

Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml